Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.
Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This observational, non-interventional, retrospective, multicenter, national study focuses on
collecting information about the effectiveness and safety of bortezomib re-use at first
relapse in MM patients already treated in their first line with a bortezomib-based regimen,
re-challenged with the same drug according to current clinical practice and/or Italian
SIE/SIES/GITMO, IMWG and/or NCCN Guidelines/Treatment Recommendations.
Data will be collected retrospectively from approximately 25 haematologic/oncologic sites in
Italy. Approximately, data of up to 100 patients will be collected.
Details
Lead Sponsor:
IRCCS Centro di Riferimento Oncologico della Basilicata